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ABSTRACT
Motivation.Predominantpathwayanalysisapproachestreatpathwaysascollections
of individual genes and consider all pathway members as equally informative. As
a result, at times spurious and misleading pathways are inappropriately identiﬁed
as statistically signiﬁcant, solely due to components that they share with the more
relevantpathways.
Results. We introduce the concept of Pathway Gene-Pair Signatures (Pathway-
GPS) as pairs of genes that, as a combination, are speciﬁc to a single pathway. We
devised and implemented a novel approach to pathway analysis, Signature Over-
representation Analysis (SIGORA), which focuses on the statistically signiﬁcant
enrichmentofPathway-GPSinauser-speciﬁedgenelistofinterest.Inacomparative
evaluationofseveralpublisheddatasets,SIGORAoutperformedtraditionalmethods
bydeliveringbiologicallymoreplausibleandrelevantresults.
Availability.AneYcientimplementationofSIGORA,asanRpackagewithprecom-
piled GPS data for several human and mouse pathway repositories is available for
downloadfromhttp://sigora.googlecode.com/svn/.
Subjects Bioinformatics, Computational Biology, Molecular Biology, Immunology, Infectious
Diseases
Keywords Systems biology, Functional analysis, Over-representation analysis, Pathway analysis,
Shared components, High-throughput data
INTRODUCTION
Pathway analysis identiﬁes biological pathways that are statistically enriched in a given
dataset and plays a crucial role in the interpretation of high-throughput experimental
datasets including gene or protein expression proﬁles (Khatri & Dr˘ aghici, 2005; Huang,
Sherman & Lempicki, 2009) and genome-wide association studies (GWAS) (Wang, Li &
Hakonarson, 2010). Pathway analysis can guide the understanding of complex biological
datasets through the statistical association of observations at the molecular level to
processes at the systems level. Such analysis can, for example, highlight processes that
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representation of their gene-pair signatures. PeerJ1:e229; DOI10.7717/peerj.229Table 1 Annotation and co-annotation of human genes in current pathway repositories. The number of human genes annotated in pathways in
the KEGG, Reactome and PID databases. On average more than 40% of genes are annotated in more than one pathway whereas gene-pairs rarely
co-occur in multiple pathways.
Pathway
database
Numberof
annotatedgenes
%ofgenesannotated
inasinglepathway
%ofgenesannotated
inmultiplepathways
Numberof
co-annotated
gene-pairs
%ofgene-pairs
thatco-occur
inasinglepathway
KEGG 5,660 48% 52% 1,205,807 90%
REACTOME 5,046 62% 38% 197,034 87%
PID BIOCARTA 1,368 54% 46% 32,361 78%
PID NCI 2,374 51% 49% 116,852 87%
are dysregulated in certain pathological conditions, such as cancer (Copeland & Jenkins,
2009)orinfection(Wherryetal.,2007).
Currently, two types of pathway analysis methods are widely used: Over-representation
Analysis (ORA) methods (reviewed in Khatri & Dr˘ aghici, 2005) and methods related
to Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005;
Dinuetal.,2009).
Despite major diVerences between ORA and GSEA methods (see e.g., Emmert-Streib
& Glazko, 2011, for a discussion), these approaches share a notable limitation: most
current methods treat all genes in a given pathway as equal indicators that that pathway is
signiﬁcant.Thisassumption,thateachgeneinapathwayhasthesamepowertodistinguish
one pathway from another, and that genes assume their roles without consideration of the
context and expression of other genes, is undoubtedly ﬂawed (Gillis & Pavlidis, 2011; Ma,
Sartor&Jagadish,2011;Khatri,Sirota&Butte,2012).
To illustrate this point, consider four protein kinases, PRKACA, PRKACB, PRKACG,
and PRKX. Within the KEGG (Kanehisa et al., 2011) pathway repository, these genes are
members of 24 diVerent pathways, i.e., they co-occur in roughly 10% of KEGG human
pathways (Fig. 1). Consider a dataset where all four of these genes were observed to be
diVerentially expressed — many pathway analysis tools would identify all 24 diVerent
pathways as statistically signiﬁcant leaving the biologist perplexed as to which of these
pathways are the most biologically relevant to their study. The underlying problem (that
genes may be associated with multiple pathways and, as such, that all genes are not
equivalent “Signatures” of a given pathway) is widespread and not limited to kinases.
WithinKEGG,52%ofgenesareannotatedinmorethanonepathway(Table1).
As a result, many pathway analysis methods return misleading statistically signiﬁcant
pathways that are signiﬁcant solely due to shared components with other pathways (e.g.,
“Prion Disease” is identiﬁed as a signiﬁcant pathway in a dengue fever microarray study
(Hoang et al., 2010) simply because many of the genes annotated in this “pathway” are
co-annotatedininﬂammation-relatedpathways).
Here, we report a novel approach to address this problem, which involves the iden-
tiﬁcation of statistically over-represented Pathway Gene-Pair Signatures (Pathway-GPS)
(i.e., weighted pairs of genes which uniquely occur together in a single pathway). The
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 2/27Figure1 NotallgeneshavethesamepowertodistinguishbetweendiVerentpathways.Inthisexample,
all current KEGG annotations of seven selected genes are shown. Red: annotated in pathway; white: not
annotated in this pathway.
use of such gene pairs is also motivated by the data in Table 1: in contrast to single
genes, co-annotated gene pairs tend to be speciﬁc to a single pathway. We provide an
implementation of this approach in R (SIGORA; downloadable from http://sigora.
googlecode.com/svn/). We describe this approach and demonstrate how SIGORA
signiﬁcantly reduces the identiﬁcation of spurious pathways in analyses of simulated and
realbiologicaldatasets.
MATERIALS AND METHODS
Algorithm
As illustrated in Fig. 2, our approach to the problem consists of two phases: In an oZine
phase, we compile a set of weighted markers/Signatures for each pathway in a repository,
which we call Pathway Gene-Pair Signatures (Pathway-GPS). Subsequently, in an online
phase, the method identiﬁes the statistical over-representation of such Signatures in a
user-speciﬁedgenelistusinganadaptedversionofthehypergeometrictest.
Given a pathway repository (e.g., KEGG), for each gene-pair in a pathway, SIGORA
investigates the co-appearance of the two genes in other pathways of the repository.
A gene-pair that uniquely occurs in a single pathway is considered a Signature of that
pathway and is assigned a weight. The weight of a Signature (from [0, 1]) quantiﬁes
the average commitment of the components of the GPS towards the common pathway,
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 3/27Figure2 SIGORA’stwophases.IntheoV-linephase(left)apathwayrepositoryistransformedtodisjoint
sets of weighted GPS. These precompiled signatures are used in the on-line phase (right) to evaluate a
user speciﬁc input gene list.
i.e.,theweightscoresthereliabilityoftheSignatureasevidencefortheassociatedpathway.
For hierarchically organized repositories (like REACTOME (Matthews et al., 2009)),
this process is repeated iteratively after the removal of pathways on the top level of the
repository, i.e., in each iteration, new weighted Signatures are identiﬁed for the pathways
on the lower, more speciﬁc levels of the hierarchy. Once this oZine stage is completed, the
resultingsetsofweightedgene-pairsthatrepresenteachpathwayarenon-overlappingand
canbere-usedforpathwayanalysisofanyuser-speciﬁedgenelists.
Whenpresentedwithagenelistofinterest(e.g.,genesthatarediVerentiallyexpressed),
SIGORA determines which of the pairs from its (pre-compiled) Signature repository can
be reconstructed from the genes in the list. A Signature is considered “present” only if
both of its constituent genes are found in the user-speciﬁed query list. This inherently
leads to the selection of the more relevant roles of a gene in the experimental context, as
SIGORA relies on the status of the other genes in the pathway for the reconstruction of
the Signatures. For each pathway, the weights of present Signatures are summed up and
hypergeometric probabilities are used to assess the statistical signiﬁcance of the observed
Signaturesets.
Pathway Gene-Pair Signatures (Pathway-GPS)
Apathwaydatabase/repositorycontains(atleast)twotypesofentities:pathwaysandgenes.
This can be represented by a bipartite graph (or bipartite network) B D .Vg;Vp;E/ with
two distinct sets of nodes (Vg: gene nodes and Vp: pathway nodes) where the edges in
E connect the genes to the pathways and signify the annotation of a gene in a particular
pathway (Fig. 3A). In this graph, the degrees (number of incident edges) of the pathway
nodes correspond to pathway sizes (i.e., the number of genes annotated in the pathway)
andthedegreeofthegenenodescorrespondstothenumberofdiVerentpathwaysageneis
annotatedin.Inparticular,geneswithdegreeoneareexclusivelyannotatedwithinasingle
pathway(‘Pathway Unique Genes (PUGs)’).
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 4/27Figure 3 Overview of the signature transformation. (A) A schematic pathway repository as a bipartite
graph (B); G1...G5: genes; P1...P3: pathways. (B) A pathway unique gene. (C) A Gene-Pair Signature
(GPS):G3andG4co-occuronlyinP2.(D)EachGPSisassociatedwithasinglepathwayandhasaweight
equal to the average inverse degree (in B) of its constituent genes.
Using the igraph (Csardi & Nepusz, 2006) package of the R-Statistical Framework
(R Development Core Team, 2008), B can be manipulated and transformed. A weighted
one-mode projection (Newman, 2001) of B into the gene dimension, yields a new graph
Proj D .Vg;E0;W/ with only one type of nodes (only gene nodes Vg), where two genes are
connectedbyanedgeinE0 if(andonlyif)theyareco-annotatedinoneormorepathways,
and each edge is associated with a weight (in W) which signiﬁes the number of pathways
that are shared between the two incident genes (i.e., the two genes connected by the edge).
Two genes connected by an edge of weight one in Proj are, as a combination, unique to a
single pathway. We call such pairs Pathway Gene-Pair Signatures (Pathway-GPS) of that
pathway. The process of identifying PUGs and Pathway-GPS for all pathways in a given
repositoryistermedthe‘Signature Transformation’oftherepository.
Hypothetically,onecouldgobeyondgene-pairsandalsoconsidern-tuples(withn > 2)
of genes that co-occur in a single pathway P as signatures of P. The possible beneﬁts of
such extensions, however, do not currently seem to justify the associated complications to
the computational and methodological framework. This point is further discussed in the
TextS1.
Assignment of weights to GPS
As, by deﬁnition, each Pathway-GPS is uniquely associated with a single pathway,
identifying such Signatures in a gene list of interest (e.g., observing that both constituent
genes of a Pathway-GPS are in the list of diVerentially expressed genes) can serve as an
indicator of the activation/perturbation of the associated pathway. Each pathway can
(and usually does) have multiple possible Pathway-GPS, and (as discussed below) the
method does not rely on the observation of an individual GPS but rather on the statistical
over-representationofmultipleGPSincomparisontotheexpectedproportion.
Yet before the over-representation of GPS can be used for the identiﬁcation of relevant
pathways, we need to emphasize that diVerent GPS vary in their reliability as indicators
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a Pathway-GPS can only be co-annotated in a single pathway, each of the two genes
–considered individually–canbeamemberofseveraldistinctpathways.
Consider GPS of the form (g1;g2) for a pathway P, where g1 is annotated in i pathways
and g2 is in j pathways. Intuitively, a GPS that consists of two PUGs (i.e., a case where
i D j D 1) is a more appealing signature than a GPS that consists of two ‘multifunctional’
genes(say,i D 4andj D 3),wherethesimultaneousobservationofthetwogenesmightbe
duetootherfactors(e.g.,simultaneousactivationoftwodiVerentpathways).
To address this issue, a weight is assigned to each GPS to quantify its reliability as an
indicator of its associated pathway. Let (g1, g2) be a GPS associated with a pathway P and
letiandj bethenumberofindividualpathwaysannotationsofg1andg2,respectively.The
weightoftheGPSis
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Amotivationforthisweightingschemeandadiscussionofalternativeweightingstrategies
can be found in the Text S1. In the implementation, the user also has access to several
alternative weighting schemes and user deﬁned schemes are also supported. Figure 3
summarizes the main ideas behind the compilation of weighted Signatures for a given
pathwayrepository.
Identifying statistically over-represented Pathway-GPS
Analogous to traditional (individual gene) ORA (IG-ORA) methods, the distribution
function of hypergeometric probabilities is used to calculate p-values indicating the
statisticalenrichmentofPathway-GPSinauser-speciﬁedgenelist,whichisgivenby:
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In individual gene ORA, k denotes the number of query genes in the tested pathway, n the
number of the genes in the pathway, N the number of all (assayed or annotated) genes,
and m the length of the query list (i.e., the number of the genes with interesting status). In
contrast to these traditional approaches, however, the parameters of the hypergeometric
functioninSIGORAarecalculatedassumsofGPSweightsratherthanfrequencystatistics
ofindividualgeneannotations.TheSignatureORAparametersforp-valuecalculationsare
summarizedinTable2.
Note that – strictly speaking – hypergeometric probabilities are only deﬁned on natural
numbers while the sums of GPS weights are positive ﬂoating point values, which is why
the table refers to rounded values of the sums (to the closest integer). Theoretically, this
rounding could lead to a ‘blurring of the weights for pathways with few GPS’, however, in
practice this issue hardly materializes, as such pathways are very rare (e.g., 219 out of 226
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 6/27Table2 InterpretationofthehypergeometricdistributiontestparametersusedinSIGORA. A GPS is
present if both of its component genes are in the query list.
Parameter InterpretationinSIGORA
k (success) Rounded sum of the weights of all present GPS of the tested pathway
n (success states) Rounded sum of the weights of all possible GPS of the tested pathway
N (universe) Rounded sum of the weights of all possible GPS of the repository
m (sample size) Rounded sum of the weights of all present GPS
KEGGhumanpathwaysinourrepositoryareassociatedwith10ormorepossibleGPS).In
testswithsimulatedandrealbiologicaldatasets,diVerentchoicesoftheroundingstrategy
(ﬂoor, ceiling or nearest integer) did not substantially aVect the signiﬁcance or the rank
order of the identiﬁed pathways. As an aside, in the widely popular statistical framework
R, the phyper function (which computes the distribution function of the hypergeometric
distribution) does accept non-integer (ﬂoating point) parameters and handles such input
byapplyingthefollowingroundingstrategy:thenumberofsuccessesisroundeddown,all
remainingparametersareroundedtotheclosestintegervalue.
In our implementation, the user has the option to restrict the GPS-sets for the
universe .N/, and the success states .n/ by providing a list of assayed genes (background).
Furthermore, all PUGs are by default considered to represent a GPS of weight 1 (as a
combination of the PUG with itself), but the user has the option to restrict the analysis to
pairsofgenuinelydistinctgenes.
Multiple testing correction
Undertaking pathway analysis generally involves a large numbers of signiﬁcance tests.
As testing a multitude of hypotheses will inevitably lead to some ‘signiﬁcant’ results,
adjustment of p-values for multiple testing is a crucial feature of any pathway analysis
tool. Bonferroni’s method is used by default in SIGORA for multiple testing correction
(MTC). It is, however, relatively easy to change the MTC procedure, if a user prefers to
exploreotheradjustmentmethods(seetheimplementationsection).
Selection of cut-off threshold for statistical signiﬁcance of
pathways
Thechoiceofareasonablecut-oVthresholdforstatisticalsigniﬁcanceofthehypergeomet-
ric test results is an open methodological question in IG-ORA. In practice, values smaller
than 0.1 or 0.05 after correction for multiple testing are commonly considered signiﬁcant.
ShiftingtheperspectivefromindividualgenestotheweightedGene-PairSignaturesbrings
anadditionalchallenge:asthesizeoftheuniverseforthehypergeometrictestdramatically
increases (we move from a few thousand genes to up to a few hundred thousand weighted
gene-pairs), the calculated p-values become by several orders of magnitude smaller than
thoseobservedinatypicalIG-ORAanalysis.
Based on our experience with simulated and biological datasets, we recommend a
signiﬁcance threshold of 0.001 after MTC (by Bonferroni). In the implementation, the
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up to this value. The user can also export the entire results table (including the p-values,
correctedp-valuesandtheparametersofthehypergeometrictest)andtheevidence(listsof
presentPUGs,listofthegenesinvolvedinpresentGPSorlistofallpresentGPSalongwith
theirweights).
Dealing with redundancies of semantic origin
Thusfar,wehavedescribedthemotivationforSignatureTransformationfromabiological
perspective. However, in some cases, there are additional semantic reasons for sharing
of components among pathways. In particular, some repositories (e.g., REACTOME
(Matthews et al., 2009), INOH (Yamamoto et al., 2011) and Gene Ontology (Ashburner
et al., 2000)) are organized in a hierarchical structure, where all genes associated with one
pathway(child)arealsoincludedinamoregeneralpathway(parent).Thisposesageneral
challenge for pathway analysis tools that ideally should identify the most relevant level
of the hierarchy (Alexa, Rahnenf¨ uhrer & Lengauer, 2006; Grossmann et al., 2007; Jupiter,
Sahutoglu&VanBuren,2009).
Thehierarchicalnatureofsuchrepositoriesposesaspecialchallengeforourmethod.As
any gene-pairs from a child category also co-occur in the parent pathway, they would thus
beexcluded frombeing identiﬁed asa possibleSignature. This wouldhave theundesirable
eVect that all child pathways on the lower levels of the hierarchy would be left without any
Signatures at all in the oZine stage and hence be undetectable by SIGORA in the online
stage.
To address this issue, we deploy the following iterative top-down strategy in the oZine
stage(SignatureTransformation):
1. Set level D 1. Compile the repository Signatures as described for the non-hierarchical
case.Assignthecompiledsignaturestolevel1.
2. Removeallpathwaysfromthetoplevelofthehierarchy,increasethelevelandrecompile
Signatures for the remaining pathways. Assign the GPS to the current level. Iterate this
stepuntilnofurtherhierarchicallevelscanberemoved.
Figure S1 illustrates this procedure on a simpliﬁed hierarchical repository. In the online
stage(theidentiﬁcationofsigniﬁcantlyover-representedSignaturesinauser-speciﬁedgene
list)theusercanspecifyhowmanylevelsofthehierarchyshouldbeconsideredintheanal-
ysis. Any GPS (and any pathways) that are deeper down the hierarchy (i.e., are at a higher
thresholdlevel)areleftoutoftheuniverse(andtheanalysis).Iftheuser(forinstance)asks
foranalysisuptothesecondlevel,thenonlyGPSfromlevelsoneandtwoareconsidered.
The eVect of this simple modiﬁcation (i.e., the iterative strategy for Signature Transfor-
mation) is similar to a combination of the Elim (Alexa, Rahnenf¨ uhrer & Lengauer, 2006),
and TreeHugger (Jupiter, Sahutoglu & VanBuren, 2009) algorithms in dealing with GO’s
structure.Elimessentiallyexcludesgenesinmorespeciﬁccategoriesfromconsiderationin
moregeneralcategories,whereasTreeHugger weakensthecontributionofsuchgenestothe
higherlevels.
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 8/27Complexity and computational cost of the method
The complexity of the transformation step (in an implementation based on the outlined
bipartite network interpretation of gene-pathway membership) is dominated by the
complexityofthebipartiteprojection,whichisgivenas:
O.kVkd2 CkEk/
With kVk: number of nodes in the network (number of genes C number of pathways), d
theaveragedegreeofnodes,kEkthenumberofedgesinthebipartitenetwork.
For most inputs, the online phase (i.e., analysis of user speciﬁc input lists using the
precompiled Signatures) completes within 15 s on a standard laptop (1.8 GHZ, 2 GB of
RAM).
Implementation
SIGORAisimplementedasanRpackage.Thepackageandadetailedmanualareavailable
for download from http://sigora.googlecode.com/svn/. The following highlights the most
importantstepsinatypicalwork-followinR(requiresRversion2:10):
##installandloadthedownloadedpackage
>install.packages(‘sigora 0.9.8.tar.gz’,type=‘source’,repos=NULL)
>library(‘sigora’)
##(pleasenotethatallofthefollowingcommandsrequirethatthepackageisalreadyloaded)
##importthequerylistfromaﬁle(assumingthelistisgivenasEnsemblgeneIDs):
>myquerylist<-ens converter(scan(‘myﬁle.txt’,what=‘character’))
##Alternatively,iftheﬁleconsistsofEntrezgeneIDs
>myquerylist<-entrez converter(scan(‘myﬁle.txt’))
##performsignatureover-representationanalysis,usingKEGGGPS
>sigs(myquerylist,‘k’,markers=1,level=2)
##multipletestingcorrectionisdonebyBonferroniandFDRsarealsoprovided.
InordertoaddHommel’smethod:
>cbind(summary results,p.adjust(summary results[,5],‘hommel’))
##exporttheresultsintoaﬁle
>export results(ﬁlename=‘my results.csv’,genes=T)
##help(onWindowssystems,helpisshownintheweb-browser)
>help(sigs)
##thefollowingdemoisalsoavailable
>demo(sigora)
Evaluation methods
WeevaluatedtheperformanceofSIGORAbycomparisontoseveralotheranalysistoolson
simulatedandpublishedbiologicaldatasets.Threeofthemethodscomparedarebasedon
individualgeneover-representation(DAVID(Huang,Sherman&Lempicki,2009;Jiaoetal.,
2012), gProﬁleR (Reimand et al., 2007), InnateDB (Lynn et al., 2008)) and the remaining
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Jagadish, 2011)) are GSEA based. Acknowledging the inherent challenges associated with
comparison of p-values across diVerent statistical frameworks, for each tool we follow the
recommendations of the authors of that tool regarding the choice of the most appropriate
signiﬁcancethresholdandmultipletestingcorrection(MTC)method(TextS1).
Among the methods listed above, we use DAVID, gProﬁleR, GSEA PRERANKED for
the simulation study, as these tools (like SIGORA) can be run on any pre-selected gene list
and in ‘batch mode’. GSEA and Appearance frequency modulated GSEA (AF) are limited
to particular experimental designs and have speciﬁc input data format requirements,
and are used here only in the analysis of three biological dataset for which data in the
required input format was available. InnateDB is used as a reference point in evaluation
of the biological datasets, because SIGORA’s GPS are based on pathway annotation data
as present in InnateDB. The rationale for selecting GSEA is its popularity; while AF was
chosenbecauseitattemptstoaddresssimilarissuesasSIGORA.
Ashortsummaryoftherelevantcharacteristicsofeachofthesemethodsisgivenbelow.
InnateDB (www.innatedb.com (Lynn et al., 2008; Breuer et al., 2013))
InnateDB’spathwayanalysisinterfaceprovidestraditionalIG-ORAusingthestandardhy-
pergeometric test. Its recommended MTC method is Benjamini–Hochberg. The pathway
GPS in SIGORA’s current implementation are calculated using the pathway annotation
as present in the latest release of InnateDB. In other words, any observed diVerences in
analysis results between SIGORA and InnateDB are solely due to the diVerences between
Signature-over-representation and individual-gene over-representation, and there are no
additional confounding issues regarding the gene identiﬁer mapping or diVerent update
status of the repositories across tools. We compare InnateDB to SIGORA using three
biologicaldatasets.
gProﬁleR (http://biit.cs.ut.ee/gprofiler/(Reimand et al., 2007))
gProﬁleR is the R package associated with the web-server of same name. Like InnateDB, it
deploysatraditionalindividualgeneover-representationbasedmethodusingthestandard
hypergeometrictest.IngProﬁleR,p-valuesarecorrectedbydefaultusingauniquemultiple
testingcorrectionmethod(MTC),calledtheSetCountsandSizes(SCS)procedure,which
is analytically derived from extensive simulation experiments and purports to account
for “the actual structure behind functional annotations”. In other words, issues relating
to the overlapping structures within annotation repositories are believed to be addressed
indirectly and implicitly, as a special case of MTC. We use gProﬁleR in the simulation
experiment. For completeness, we also list gProﬁleR’s results on the three biological
datasets evaluated here; however, some of the pathways listed by gProﬁleR are very recent
additionstotheKEGGrepositorythatareasyetnotavailableinothertools,includingour
currentimplementationofSIGORA.
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Jiao et al., 2012))
DAVID provides individual-gene pathway analysis over-representation analysis using the
EASE Score, a modiﬁed Fisher Exact p-value that is designed to raise the bar for statistical
signiﬁcance of smaller pathways. This avoids situations in which observation of only a
few genes from a small pathway would make it equally (or even more) signiﬁcant than
observing dozens of genes from a larger pathways. The EASE Score is generally more
conservativethantheFisherExactp-values.
Apart from this modiﬁcation, DAVID’s functional annotation charts implement a
traditional individual gene over-representation based method that treats all genes
equally. DAVID has also introduced the concept of functional annotations clusters that
aremotivatedbytheideathatratherthanfocusingonsigniﬁcanceofindividualpathways,
the true nature of a phenotype should be examined by considering the overall emerging
picture of interrelated pathways. In some situations, clusters of interrelated pathways can
be considered collectively signiﬁcant while some (or most) of the individual pathways
in those clusters might fall slightly beyond the signiﬁcance threshold. Although this
is undoubtedly a sensible statement, the measure of interrelatedness used in DAVID’s
functional clusters is in diametrical contrast to the reasoning behind SIGORA: DAVID’s
authorspostulatethatsimilarpathwaystendtocontainsimilargenemembers.InDAVID’s
functional annotation charts, the more common genes annotations share, the higher
chancetheywillbegroupedtogetherasinterrelatedpathways,andthebetterthechancesof
theemergingclustertobecome(collectively)signiﬁcant.
For the simulation experiment, we will focus on DAVID’s functional charts. In our
evaluation of analysis results on biological datasets, we will also brieﬂy exemplify the
pitfallsofDAVID’sFunctionalclusters.
GSEA (Subramanian et al., 2005)
The three methods discussed above (InnateDB, gProﬁleR and DAVID) are over-
representation based methods that (like SIGORA) operate on a pre-ﬁltered list of genes of
interest (query list). The list of genes of interest is often determined using a (combination
of) threshold(s) (e.g., foldchange and p-value of diVerential expression). Thep-values are
inessencederivedfromacontingencytable.
GSEA, in contrast, is the most prominent representative of a very diVerent category of
pathwayanalysistoolsthatdonotoperateonapre-selectedlistanddonotusecontingency
tables. In GSEA, all genes in the dataset are ﬁrst ranked by their diVerence regarding a
singlebiologicalmetric(e.g.,signaltonoiseratio)betweenthetwoconditions.Thisranked
gene list is then used to assign a normalized enrichment score (NES) – deﬁned as the
maximumdeviationofarunningsumstatisticfromzero,adjustedforthenumberofgenes
in the pathway – to each pathway. The statistical signiﬁcance of the NES is determined by
samplepermutation(i.e.,randomlyexchangingthephenotypeclasslabels).
We compare GSEA and SIGORA in the analysis of three biological datasets. Some of
the observed diVerences in the results of GSEA analysis to SIGORA are inevitably due to
the fundamental diVerences between ORA and GSEA methods. In particular, regardless
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of some of pathways observed by GSEA is due to ‘subtle but coordinated changes’ in
expressionlevelsofgenesthatarenotinthelistofdiVerentiallyexpressedgenes.
This issue equally applies to the two remaining methods, GSEA-PRERANKED and AF,
whicharedescribedbelow.
GSEA-PRERANKED
Asthenamesuggests,thisisavariantofGSEAwheretheinputformatisnotanexpression
matrix, but a pre-ranked list of genes. Accordingly, as there is no sample information
available,thestatisticalsigniﬁcanceisderivedfromgenesetpermutationinsteadofsample
permutations. Technically, applying GSEA and GSEA-PRERANKED to the same dataset
can lead to identical NES, but very diVerent FDRs (http://www.broadinstitute.org/gsea/
doc/GSEAUserGuideFrame.html). Hence, the recommended threshold for statistical
signiﬁcance is diVerent (0.05 instead of 0.25). We compare GSEA-PRERANKED to
SIGORA in analysis of simulation datasets. Like standard GSEA, GSEA-PRERANKED
doesnotprovideamechanismfordealingwithsharedcomponentsofpathways.
Appearance Frequency modulated GSEA (AF) (Ma, Sartor & Jagadish,
2011)
AF is a recently proposed variant of GSEA that is explicitly designed to deal with issues
posed by shared components. In this respect (the intended beneﬁt), AF is the most
similar method to SIGORA among all methods compared here. AF assigns weights to
individual genes based on number of associated pathways and performs a GSEA analysis.
Methodologically, AF inherits most of GSEA’s characteristics and is quite distinct from
SIGORA.WecompareAF andSIGORAintheanalysisofthreebiologicaldatasets.
Simulation experiment
Creation of simulated input lists
As a preliminary measure to quantify the eVect of shared components on the number of
spurious pathways, we conducted a simulation experiment over 1,000s of simulated gene
lists that are created by applying the following procedure: From a set of 175 human KEGG
human pathways that are in the repository of all four compared tools (SIGORA, DAVID,
gProﬁlerandGSEA preranked),npathwaysarechosenatrandomandafraction(alpha)of
genesineachselectedpathwayaremarkedasdiVerentiallyexpressed(DE).Therestriction
to175commonpathwaysisintendedtoreducetheeVectsofdivergingupdate-statusacross
analysis tools. The list of DE genes from ﬁve selected pathways is used as a query list for
SIGORA, gProﬁler and DAVID. To create an input list for GSEA preranked, a score of 2
is assigned to the selected DE genes and a score of 1 to all remaining human genes. This
procedureisrepeated1,000timesatﬁxedvaluesforalphaandn.
Biological datasets
Wefurther compareeach ofthe diVerentpathway analysistools byexamining theirresults
when applied to three diVerent gene expression datasets. These datasets incorporate
the results of microarray studies investigating the host response to a parasite infection
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infection (Tuberculosis) (Lovegrove et al., 2007; Thuong et al., 2008; Hoang et al., 2010).
We map the lists of diVerentially expressed genes in each experiment (as provided by the
authors of the respective studies) to unique Ensembl/Entrez IDs and use the resulting sets
as input lists for four over-representation based methods (InnateDB, DAVID, gProﬁler
andSIGORA),ensuringthatallmethodsarerunonidenticalinputlists.Additionally,two
GSEA-based methods (GSEA and AF) are also applied to the corresponding expression
datasets obtained from the gene expression omnibus (GEO): GSE25001, GSE11199,
GSE11199.
RESULTS
Results on simulated gene lists
To evaluate the performance of SIGORA, we compared it to three other popular pathway
analysis methods (DAVID, gProﬁler and GSEA Preranked) applied to simulated data,
where we know a priori which are the signiﬁcant pathways. The simulated input data was
createdbyrandomlychoosingﬁveKEGGpathwaysandselectingafraction(alpha,50%or
15%) of the genes in each of these pathways as being “diVerentially expressed”. Each of the
methods was then applied to the selected gene list to determine the statistically signiﬁcant
pathways (using the respective recommended signiﬁcance threshold and MTC approach,
seeTextS1).
IfthesharingofgenesbetweendiVerentpathwayswasnotafactor,wewouldexpectthat
each method should identify only the ﬁve preselected pathways as signiﬁcant. As can be
seen in Table 3, in our experiments (using 1,000 simulated datasets with alpha D 50% and
1,000 datasets with alpha D 15%), this was not the case: gProﬁleR, for example, identiﬁed
more than 60 pathways on average as being signiﬁcant at alpha D 50%, despite only 5
pathways being simulated as signiﬁcant in the input data. SIGORA performed best by this
measureandidentiﬁedonaverage8pathwaysassigniﬁcantacrossthediVerentdatasets.
The Recalland Precisionmetrics in thethird andfourth columns ofTable 3capture the
relationship between originally preselected ‘target’ pathways and the identiﬁed pathways.
Morespeciﬁcally:Recalldescribesthefractionofthetargetpathwaysthatwereidentiﬁedas
signiﬁcantandPrecisionsigniﬁesthefractionofstatisticallysigniﬁcantpathwaysthatwere
among the originally selected pathways. Neither of these two metrics by itself is decisive,
and there is a certain trade-oV between the two metrics. This trade-oV is captured by the
F1-score, the harmonic mean of Precision and Recall. As can be seen in Table 3, SIGORA
hadthebestF1scoreswhencomparedtotheothermethods.
Finally, note that although this analysis is based on recommended signiﬁcance thresh-
olds in each method, Precision, Recall and F1 score are all dependent on the – ultimately
arbitrary – choices of signiﬁcance thresholds. The last column in Table 3 describes the
results according to a less threshold-dependent measure. Ideally, the preselected pathways
would occupy the ﬁrst ﬁve positions in the list of the identiﬁed pathways, resulting in an
average rank of 3. As can be seen in the last column of Table 4, at both choices for alpha
(15% or 50% of the genes in each pathway selected) the average rank of the originally
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of the simulated datasets contained either 15 or 50% of genes in 5 randomly chosen pathways. For each analysis method and each input gene
list, the identiﬁed (statistically signiﬁcant) pathways were recorded and the Precision (true positive results/all signiﬁcant pathways), Recall (true
positive/chosen) and F1 score (harmonic mean of Precision and Recall) were calculated by comparing the list of the (n) chosen pathways with the list of
identiﬁed pathways. More speciﬁcally, for the purpose of this analysis, a statistically signiﬁcant pathway is considered a true positive if it is among the
ﬁve chosen pathways and a false positive otherwise; furthermore, any chosen pathways that are not identiﬁed by a method as statistically signiﬁcant
are considered false negatives. The entries in bold show the method with the best performance according to each measure.
Alpha Method Averagenumber
ofsigniﬁcant
pathways
Average
Recall
Average
Precision
F1score(harmonic
meanofPrecision
andRecall)
Averagerankofthe
originalpathwayswithin
theanalysisresults
DAVID 11.22 0.71 0.32 0.44 6.8
gProﬁler 34.17 0.95 0.14 0.24 7.8
GSEA Preranked 0.09 0.01 0.74 0.03 29.6
15%
SIGORA 6.41 0.72 0.56 0.63 3.6
DAVID 30.25 0.98 0.16 0.28 6.8
gProﬁler 62.48 0.99 0.08 0.15 8
GSEA Preranked 13.91 0.87 0.32 0.46 5.6
50%
SIGORA 8.87 0.89 0.50 0.64 3.7
preselected pathways (‘target pathways’) in SIGORA’s results (3.6 and 3.8 respectively) is
veryclosetothisidealvalue,whereastheothermethodstendtoidentifyseveraladditional
pathwaysasmoresigniﬁcantthanthetargetpathways,resultinginhigheraverageranksof
targetpathwaysinthesemethods.
Results on published datasets
In addition to the simulated data, we also compared SIGORA to ﬁve diVerent methods
(InnateDB, DAVID, gProﬁleR, GSEA and AF) applied to real biological data, in this
case three diVerent gene expression datasets. Full details of the input genes, p-values and
highlightedpathwaysobtainedbyeachmethodcanbefoundintheTablesS1–S3.
Tuberculosis
SIGORA was compared to ﬁve diVerent pathway analysis methods (InnateDB, DAVID,
gProﬁleR,GSEAandAF)appliedtoageneexpressiondataset(GSE11199)whichmeasured
the host transcriptional response in human macrophages infected with Mycobacterium
tuberculosis (Thuong et al., 2008). 1,250 transcripts (corresponding to 1,100 distinct
Ensembl genes) were identiﬁed by Thuong et al. as being induced in response to this
infection. Figure 4 shows the pathways that were identiﬁed as statistically signiﬁcant by
each of the six methods. The ﬁrst thing that one notes is that the GSEA-based methods
tended to predict large numbers of pathways as statistically signiﬁcant (the AF method
predicted nearly a third of the KEGG database as signiﬁcant in this example). This is
somewhatbydesign,asGSEAmethodsattempttoidentifysubtlebutcoordinatedchanges
in gene expression. This may be very helpful in investigating cases where there are only
subtle diVerences between conditions but in a dataset like this one, it leaves the biologist
bewildered as to which pathways should be followed-up on experimentally. In the other
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 14/27Table 4 List of all pathways identiﬁed as statistically signiﬁcant by each method compared in this
study and their respective ranks (by p-value) in the analysis of a Dengue fever gene expression
dataset. The entries in bold are signiﬁcant largely due to sharing genes with other more relevant
pathways.
DAVID GSEA AF gProﬁleR InnateDB SIGORA
Systemiclupuserythematosus 1 3 2 1 1
Hepatitis C 10 2
Complement and coagulation cascades 2 3 3 3
RIG-I-like receptor signaling pathway 1 3 9 4
Cytosolic DNA-sensing pathway 2 1 4 5
Osteoclast diVerentiation 7 6
Chemokine signaling pathway 6 7
Lysosome 8
Antigen processing and presentation 9 9
NOD-like receptor signaling pathway 4 4 10
Toll-like receptor signaling pathway 6 8 5 11
Staphylococcusaureusinfection 2
Long term potentiation 10
Leishmaniainfection 5 11
Ribosome 5
Malaria 6
Allograft rejection 7
Priondiseases 12 8
Measles 1
Inﬂuenza A 2
Herpes simplex infection 4
Pertussis 5
extreme is DAVID, which predicted only 4 pathways as statistically signiﬁcant. SIGORA,
on the other hand, identiﬁed 12 pathways as statistically signiﬁcant; 10 of which were also
identiﬁedbyatleasttwoothermethods.ComparingthepathwaysidentiﬁedbySIGORAas
signiﬁcanttothesigniﬁcantpathwaysidentiﬁedbytheothermethods,onecansee(Fig.5)
that many of the pathways identiﬁed by other methods as signiﬁcant but not by SIGORA
sharemanygeneswiththeSIGORApathways.Notably,afterremovingthemultifunctional
genes that are involved in the pathways identiﬁed by SIGORA from the input list, the
individual gene over-representation based methods (DAVID, InnateDB and gProﬁleR)
did not return any signiﬁcant pathways at all. This reinforces our observation from the
simulated data that SIGORA will identify truly signiﬁcant pathways but avoid identifying
pathwaysthataresigniﬁcantbecausetheysharegeneswithothermorerelevantpathways.
Interestingly, SIGORA may also be able to identify some important pathways that are
not signiﬁcant using other methods. One pathway was identiﬁed as signiﬁcant in this
dataset only by SIGORA; FcR-mediated phagocytosis. Fc receptors regulate immune
activation and susceptibility during Mycobacterium tuberculosis infection (Maglione et al.,
2008; Maertzdorf et al., 2011) and it has been implied that “entry through Fc receptors
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Results of six diVerent pathway analysis methods applied to a gene expression dataset measuring the
hosttranscriptionalresponsetoM.tuberculosisinfectionofhumanmacrophages.Theheatmapshows
all pathways that were identiﬁed as statistically signiﬁcant by at least one of the six diVerent pathway
analysis methods. The more red the color the higher the rank of that pathway for a particular method.
The heatmap is sorted by the number of methods identifying a particular pathway as signiﬁcant.
may specify a distinct intracellular traYcking pathway for virulent M. tuberculosis” (Ernst,
1998). Finally, DAVID’s top functional cluster for this dataset (Enrichment score 0.99)
contained16pathways,12ofwhicharediVerentcancersubtypes(TableS1).
Table S1 lists all Pathways identiﬁed as statistically signiﬁcant by each of the considered
methodsandtheirrespectiveranks(byp-value)inanalysisofthisdataset.
Experimental cerebral malaria
Example 2 is a mouse cerebral malaria (ECM) dataset, comparing the whole-brain
transcriptional responses of genetically susceptible (C57BL/6) and resistant (BALB/c)
inbred mouse strains 6 days after infection with Plasmodium berghei ANKA (NCBI GEO:
GSE7814)(Lovegroveetal.,2007).WeﬁstperformedadiVerentialexpressionanalysisusing
Geo2R to obtain a list of up-regulated genes at FDR <0.01 (637 Ensembl genes, Table S2).
We use this list as input for SIGORA, InnateDB, gProﬁleR and DAVID, and apply GSEA
andAFtothecorrespondingexpressionmatrix.
Similartothepreviousexample,thenumberofKEGGpathwaysthatdiVerentmethods
identiﬁed as statistically signiﬁcantly enriched in this dataset varied widely: AF identiﬁed
59 pathways (out of 185 in its repository), while DAVID highlighted just two pathways.
SIGORA identiﬁed 14 pathways as signiﬁcant, 13 of which were also reported by at least
two other methods (Fig. 6, Table S2). The remaining pathway is PPAR signaling pathway
(discussedfurtherbelow).
Aside from this big-picture view, the strong changes in the rank orders of the following
individualpathwaysarealsoworthmentioning:
Complement and coagulation cascades
This pathway is the 6th ranked pathway in SIGORA’s results. Three additional tools
(InnateDB,GSEAandAF)alsoidentifythispathwayassigniﬁcant,butonlyatconsiderably
lowerranks(the17th,25thand27thposition,respectively).Complementandcoagulation
pathways have been shown to be critically involved in the development of ECM (Van der
Heydeetal.,2006;Francischetti,Seydel&Monteiro,2008;Ramosetal.,2012).
Leukocyte transendothelial migration
This pathway is the 7th ranked pathway in SIGORA’s results, the 23rd ranked pathway in
GSEA and the 44th ranked pathway in AF. The remaining methods do not identify this
pathway as statistically signiﬁcant. Polymorphonuclear leukocyte recruitment has been
shown to be responsible for increased permeability of the blood–brain-barrier, and is
stronglyassociatedwithfatalityratesinECM(Senaldietal.,1994;Bell,Taub&Perry,1996).
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 17/27Figure 5 Number of diVerentially expressed genes that are shared between SIGORA’s pathways (ver-
tical axis, ordered by rank) and additional pathways identiﬁed as signiﬁcant by other methods on the
TBdataset.
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 18/27Figure 6 Comparison of results of six diVerent methods on a mouse experimental cerebral malaria
dataset. The heatmap shows all pathways that were identiﬁed as statistically signiﬁcant in at least one of
ﬁve diVerent pathway analysis methods. The more red the color the higher the rank of that pathway for a
particular method. The heatmap is sorted by the number of methods identifying a particular pathway as
signiﬁcant.
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This pathway is at position 14 of SIGORA’s results. The only other method to identify
PPAR signaling is AF, at position 47. Targeting of PPAR is currently being explored as
a novel adjunctive therapy for cerebral malaria (Balachandar & Katyal, 2011; Serghides,
2012). Notably, PPAR has been reported to be one of only two genes in a cerebral
malaria-resistance locus identiﬁed using a genome-wide analysis of 32 diVerent inbred
mouse lines (Bopp et al., 2010) and modulation of the inﬂammatory response to P. berghi
infection by an antagonist of this gene has greatly enhanced the survival rates in mice
(Serghidesetal.,2009).
At the same time, SIGORA avoids a few biologically implausible pathways that are
considered highly signiﬁcant by at least two other methods: e.g., “Staphylococcus aureus
infection” (a bacterial infection) is the most signiﬁcant pathway in InnateDB’s results, and
thesecondhighestrankedpathwayingProﬁleR’sresults,butisnotsigniﬁcantinSIGORA’s
results. Similarly, GSEA and AF both identify “Prion diseases” as signiﬁcant (position 2
and 4, respectively) and again, this pathway is not signiﬁcant in SIGORA’s results. Other
examples include: “Small cell lung cancer” (GSEA, AF), “Viral myocarditis” (InnateDB,
gProﬁleR,AF),“Type I diabetes mellitus”(InnateDB,gProﬁleR)(Fig.6andTableS2).
DAVID’s top ranking functional cluster for this dataset (Enrichment Score: 2.7)
groups “Antigen processing and presentation”, “Viral myocarditis”, “Allograft rejection”,
“Graft-versus-host disease”, “Type I diabetes mellitus” and “Autoimmune thyroid disease”
together(TableS2).Allofthesepathwayshavinghighlyoverlappingannotations.
Dengue fever
As a third evaluation set, we re-examined a list of 483 up-regulated genes in the whole
blood transcriptome of patients infected with dengue virus (NCBI GEO: GSE25001)
(Hoang et al., 2010). More speciﬁcally, we compared expression proﬁles of hospitalized
patients with uncomplicated Dengue during acute phase (72 h of illness history) to
followupsamplesofsuchsubjectstwoweeksafterdischarge(n D 72).
Here, for the most part, the SIGORA results contain well-deﬁned immunity related
pathways. As before, some additional, potentially spurious pathways that are identiﬁed
by other methods are not signiﬁcant in the SIGORA analysis. Examples include
“Staphylococcus aureus infection” (the second ranked pathway in InnateDB results) and
the “Prion Disease” pathway (identiﬁed by both InnateDB and AF). These two pathways
sharecomponentswiththecomplementpathway(4and6up-regulatedgenesrespectively,
Fig.7),whichhasbeenshowntohavearoleinneutralisingDengue(Shresta,2012).
Again, this example contains a possibly relevant pathway that was signiﬁcant in
SIGORA’s results, but overlooked by the other methods: “Lysosome”, at position eight
of SIGORA’s results (Table 4, Table S3). Recent experimental evidence suggests that
manipulationofthehost’sautophagolysosomesbythedenguevirusisanimportantpartof
thevirus’slifecycle(Khakpooretal.,2009;Heaton&Randall,2010).
DAVIDdoesnotreturnanyfunctionalclustersforthisdataset.
Foroushani et al. (2013), PeerJ, DOI 10.7717/peerj.229 20/27Figure7 NumberofdiVerentiallyexpressedgenesthataresharedbetweenSIGORA’spathways(rows,
ordered by rank) and additional pathways by other methods (columns) in the analysis of the Dengue
dataset.
Discussion and related work
The existence of shared components between pathways poses a challenge for pathway
analysis methods: which of the statistically signiﬁcant pathways associated with such
components are the most biologically signiﬁcant? In 2005, Khatri and Dr˘ aghici surveyed
the state of the art analysis methods and tools of the time and outlined several limitations
as the challenges for the next generation of analysis tools. One such challenge “is related
to genes that are involved in several biological processes. For such genes, all current tools
weight all the biological processes equally. At the moment, it is not possible to single out the
more relevant one by using the context of other genes [of interest] in the current experiment”
(Khatri&Dr˘ aghici,2005).
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high throughput biological data: Several methods (Alexa, Rahnenf¨ uhrer & Lengauer,2006;
Grossmann et al., 2007; Jupiter, Sahutoglu & VanBuren, 2009) have been described to high-
lightprocessesattheappropriatelevelofspeciﬁcityandtoreducetheredundancyofthere-
sultsinthecontextofGeneOntology(GO)analysis,wheretheoverlapbetweencategories
are often due to the hierarchical organization of the ontology. These methods, however,
fail to account for overlap between pathways that don’t involve the full inclusion of all
members of a pathway in another pathway. To deal with such cases, Antonov et al. (2008)
proposed the creation of new functional categories as complex Boolean combinations of
availableGOterms.Unfortunately,suchcombinationsareoftennoteasytointerpretanda
comprehensivesearchoverallpossiblecombinationsiscomputationallyinfeasible.
Outside of GO, a few methods have been proposed that indirectly tackle the issue by
either discriminative treatment of individual genes or alternative representation of the
pathway repository in speciﬁc scenarios. An example of the later approach (alternative
representation of the pathway repository) is Bayesian Pathway Analysis, BPA (Isci et al.,
2011). BPA transforms each pathway in a pathway repository into a separate Bayesian
Network (BN) and scores the ﬁt of each model with the experimental (expression) data.
BPA is expected to leverage the expression status of other genes in the experimental
context,asBNs,incontrasttosimplelistsofgenes,aredeemedcapableofaccommodating
local interactions between genes. Although highly sophisticated, BPA is computationally
intensiveandbydesignlimitedtotheinterpretationofexpressiondatasets.
An early example of the former approach (non-egalitarian treatment of individual
genes) is impact-analysis (Draghici et al., 2007). Impact analysis integrates the magnitude
of each gene’s expression change along with the type (e.g., receptor, transcription factor)
and position of each gene within the given pathways and their interactions into the
statistical framework, however, the authors do not explicitly address the problems related
tocomponentsharingamongpathways.
More recently, it has been proposed to add an appearance frequency based parameter
to the statistical framework of GSEA. This additional parameter is intended to weaken the
contribution of genes with multiple pathway memberships to the statistical signiﬁcance
of all of their associated pathways (Ma, Sartor & Jagadish, 2011). While this is a signiﬁcant
step in the right direction, the addition of such a parameter does not exploit the status
of other genes in the experiment for the selection of the most relevant function of
a gene in the experimental context. As exempliﬁed by the gene, BRCA1 in Khatri &
Dr˘ aghici (2005), even key players of one process (maintaining genomic stability) can
have several less prominent roles in other unrelated pathways (response to nutrient and
brain development). Nor can appearance frequency distinguish between the causes of
appearance of a gene in several pathways, which, aside from functional pleiotropy of
genes, can be partly due to the hierarchical organization of some pathway repositories like
REACTOMEandGO.
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a combination) are speciﬁc to a single pathway, and we described Signature Over-
representation Analysis (SIGORA) as a novel (and comparably eYcient) approach to
pathway analysis. SIGORA uses Pathway-GPS to bridge the gap between the context
sensitiveandcollaborativenatureofbiologicalprocessesononesideandtheuniversaland
discrete statistical framework of over-representation analysis on the other side. Although
eachSignature’sweightisﬁxedinadvance,thenetcontributionofanindividualgeneGto
themeasuredsuccess(parameterkinTable1)ofeachofitsassociatedpathwaysisnotﬁxed
anddependsexplicitlyonthestatusofitspartners(genesthattogetherwithGformaGPS).
In contrast to the GSEA-based solutions, SIGORA inherits the versatility of the ORA
statistical framework and is applicable to lists of genes of interest obtained in any type of
highthroughputexperimentalset-up(e.g.,copynumbervariationsfromcellularproﬁling,
lists of epigenetically silenced genes from promoter methylation analysis, diVerential gene
expressiondatafromNGSandmicroarraysorSNPsfromGWASexperiments)withoutthe
need for adaptation of the computational method. This is especially notable in situations
where rankingof the entiredataset by asingle biologicalparameter (as requiredby GSEA)
isnotfeasible(seeHuang,Sherman&Lempicki,2009,forafewexamples).
CONCLUSIONS
Thispaperhighlightsthelevelofcomponentsharingbetweenpathwaysanddemonstrates
how this can lead to misleading/spurious results in current pathway analysis approaches
thattreatallpathwaymembersasequallyinformative.Hereweintroduceanovelapproach
that accounts for the overlapping structure of pathway annotation by focusing on unique
features (‘Signatures’) of pathways. To our knowledge, this is the ﬁrst over-representation
basedmethodtodoso.
Applied to several published datasets, our approach highlights biologically meaningful
processes that would otherwise fall below statistical signiﬁcance thresholds, and avoids
someofthebiologicallyimplausibleprocesseshighlightedbyothermethods.Thissuggests
thatourapproachdeliversausefulcomplementarytoolforpathwayanalysis.
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